Last reviewed · How we verify
Fendrix or HBVAXPRO 40 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Fendrix or HBVAXPRO 40 (Fendrix or HBVAXPRO 40) — Corporacion Parc Tauli.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fendrix or HBVAXPRO 40 TARGET | Fendrix or HBVAXPRO 40 | Corporacion Parc Tauli | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fendrix or HBVAXPRO 40 CI watch — RSS
- Fendrix or HBVAXPRO 40 CI watch — Atom
- Fendrix or HBVAXPRO 40 CI watch — JSON
- Fendrix or HBVAXPRO 40 alone — RSS
Cite this brief
Drug Landscape (2026). Fendrix or HBVAXPRO 40 — Competitive Intelligence Brief. https://druglandscape.com/ci/fendrix-or-hbvaxpro-40. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing